Pricing news · July 2026

TrumpRx and the semaglutide price deals: what actually changed

Direct-pay pricing deals have shifted the brand GLP-1 landscape. Here's what changed for semaglutide costs, and how compounded semaglutide still stacks up on real monthly cost.

EC
Eduard Cristea · Clinically reviewed by Dr. A. Goher, MD
Updated July 8, 2026
Quick answer. The 2026 pricing deals expanded brand self-pay — direct-pay Wegovy channels priced below the ~$1,349 retail pen. But that still costs more than compounded semaglutide (from ~$79, or NexLife's flat $145/month). Insured patients with a savings card may pay as little as $0–$25.

What the price deals did

The headline of the 2026 pricing shifts is that brand manufacturers expanded self-pay channels, pricing brand semaglutide below the roughly $1,349/month retail pen price. That is a real improvement for people who want the FDA-approved brand product.

But even discounted, brand self-pay generally remains meaningfully more than cash-pay compounded semaglutide for most people.

Insurance-covered patients with a qualifying diagnosis may pay far less through savings cards — sometimes $0–$25/month — but that path requires coverage.

Brand self-pay vs compounded: the numbers

Even after the deals, the cash-pay math favors compounded semaglutide for most people without brand coverage. Compounded starts around $79/month and our Editor's Pick NexLife is a flat $145/month. Brand self-pay channels remain higher, though they give you the FDA-approved product.

The right choice depends on whether FDA approval or the lowest predictable cost matters more to you.

Semaglutide monthly cost by route (cash-pay).

Bottom line for cost-conscious patients

The pricing deals narrowed the gap but did not erase it. If you want the FDA-approved brand and can absorb the self-pay price, brand channels are more accessible than before. If you want the lowest predictable monthly cost, a flat-rate compounded program remains the value pick.

Compounded GLP-1s are not FDA-approved, which is part of why they cost less — a tradeoff worth understanding before you choose.

Editor's Pick — NexLife. For a transparent flat-rate compounded semaglutide program with visits, labs, and shipping bundled, NexLife is our value pick at a flat $145/month on longer-term plans (from $155 monthly). Not the cheapest sticker — Embody is at $79 — but the most predictable all-in cost. Check NexLife pricing →

What to verify before you commit

Whatever direction you choose, a few checks protect you regardless of how the headlines change: verify the current price directly with any provider before enrolling, confirm what's included (medication, visits, labs, shipping), check whether the price changes as your dose increases, and make sure a licensed clinician is genuinely involved. Those four steps catch the most common surprises in GLP-1 telehealth.

We re-verify pricing regularly and date every figure. Use the dated numbers here as a starting point, then confirm the live price — that habit alone will save you from the majority of billing surprises, and it helps you compare accurately if you ever shop again.

The bottom line

Whatever route you choose, the fundamentals hold: semaglutide therapy works best paired with protein-forward nutrition, resistance training, and consistent clinical follow-up. The people who reach and hold an effective dose, and stay on treatment long enough for the biology to work, capture the largest and most durable results — which is why predictable cost and genuine clinician support belong in the decision alongside the sticker price.

Finally, give yourself permission to ask questions before committing. A reputable provider will clearly answer what's included, which pharmacy fills your prescription, how refills and cancellations work, and what happens if your dose changes. If those answers are hard to get, that opacity is itself useful information — it's a reason to keep looking rather than a hurdle to push past.

Treatment works best when it's sustainable, and sustainability comes from a plan you understand and can afford month after month. That's why we keep the focus on transparent, predictable pricing paired with genuine clinical support — the combination that lets you stay the course long enough to see real results.

The broader lesson across all of this is that informed patients get better outcomes and better prices. Taking a little time to understand your options — the medication, the pricing structure, the clinical process — puts you in control of a decision that affects both your health and your budget for months or years to come.

If you take one thing from this guide, let it be that transparency is your best filter. A provider that clearly shows its pricing, its pharmacy, and its clinical process has already told you most of what you need to trust it — and that clarity, paired with a price you can sustain, is what turns a good intention into lasting results.

Frequently asked questions

Did the price deals make brand semaglutide cheaper than compounded?

No, not for most people paying cash. Brand self-pay channels are more affordable than retail pens (~$1,349) but still cost more than compounded semaglutide, which starts around $79 and runs a flat $145/month at NexLife.

How much is Wegovy with the new deals?

Direct-pay channels price brand semaglutide below the ~$1,349 retail pen; exact pricing varies. Insured patients with a savings card may pay $0–$25. Confirm current terms with the manufacturer and your plan.

Is compounded semaglutide still worth it after the deals?

For cash-pay patients, yes — it remains the lowest predictable monthly cost. Brand channels are more accessible now but still higher. Compounded is not FDA-approved.

Can I get semaglutide for $25 a month?

Only with commercial insurance and an eligible savings card — that path can drop copays substantially. Without coverage, compounded semaglutide (from ~$79, or NexLife's flat $145) is the affordable route.

Key takeaways

How we rank & affiliate disclosure. This site is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded GLP-1 medications are not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.